R N Coler

Summary

Affiliation: Infectious Disease Research Institute
Country: USA

Publications

  1. ncbi request reprint Development of a leishmaniasis vaccine: the importance of MPL
    Steven G Reed
    Corixa Corporation, Seattle, WA, USA
    Expert Rev Vaccines 2:239-52. 2003
  2. ncbi request reprint Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis
    R N Coler
    The Infectious Disease Research Institute, Seattle, WA 98104, USA
    J Immunol 166:6227-35. 2001
  3. pmc Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis
    Rhea N Coler
    Infectious Disease Research Institute, Seattle, Washington 98104, USA
    Infect Immun 70:4215-25. 2002
  4. pmc Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease
    A Campos-Neto
    Infectious Disease Research Institute, Seattle, Washington 98104, USA
    Infect Immun 69:4103-8. 2001
  5. pmc Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice
    A Campos-Neto
    Infectious Disease Research Institute Corixa Corporation, Seattle, Washington 98104, USA
    Infect Immun 70:2828-36. 2002
  6. ncbi request reprint Evaluation of DPPD, a single recombinant Mycobacterium tuberculosis protein as an alternative antigen for the Mantoux test
    A Campos-Neto
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Tuberculosis (Edinb) 81:353-8. 2001
  7. doi request reprint Adjuvants for malaria vaccines
    R N Coler
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Parasite Immunol 31:520-8. 2009
  8. ncbi request reprint Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant
    Yasir A W Skeiky
    Corixa Corporation, 1124 Columbia Street, Suite 200, Seattle, WA 98104, USA
    Vaccine 20:3292-303. 2002
  9. pmc Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant
    Yasuyuki Goto
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Vaccine 25:7450-8. 2007
  10. pmc Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells
    Rhea N Coler
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Infect Immun 75:4648-54. 2007

Research Grants

Collaborators

Detail Information

Publications16

  1. ncbi request reprint Development of a leishmaniasis vaccine: the importance of MPL
    Steven G Reed
    Corixa Corporation, Seattle, WA, USA
    Expert Rev Vaccines 2:239-52. 2003
    ..This vaccine has potential application in both the prevention and treatment of leishmaniasis...
  2. ncbi request reprint Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis
    R N Coler
    The Infectious Disease Research Institute, Seattle, WA 98104, USA
    J Immunol 166:6227-35. 2001
    ..tuberculosis. Thus, these results suggest that Mtb 8.4 is a potential candidate for inclusion in a subunit vaccine against TB...
  3. pmc Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis
    Rhea N Coler
    Infectious Disease Research Institute, Seattle, Washington 98104, USA
    Infect Immun 70:4215-25. 2002
    ....
  4. pmc Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease
    A Campos-Neto
    Infectious Disease Research Institute, Seattle, Washington 98104, USA
    Infect Immun 69:4103-8. 2001
    ..The remarkable protection induced by LmSTI1 and TSA in an animal model that is evolutionarily close to humans qualifies this antigen combination as a promising candidate subunit vaccine against human leishmaniasis...
  5. pmc Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice
    A Campos-Neto
    Infectious Disease Research Institute Corixa Corporation, Seattle, Washington 98104, USA
    Infect Immun 70:2828-36. 2002
    ....
  6. ncbi request reprint Evaluation of DPPD, a single recombinant Mycobacterium tuberculosis protein as an alternative antigen for the Mantoux test
    A Campos-Neto
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Tuberculosis (Edinb) 81:353-8. 2001
    ..Because the DPPD gene is not present in non-tuberculous bacilli, these results suggest that this molecule can be an additional tool for a more specific diagnosis of tuberculosis...
  7. doi request reprint Adjuvants for malaria vaccines
    R N Coler
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Parasite Immunol 31:520-8. 2009
    ..In this minireview, we outline the current state of adjuvant research and development as it pertains to effective malaria vaccines...
  8. ncbi request reprint Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant
    Yasir A W Skeiky
    Corixa Corporation, 1124 Columbia Street, Suite 200, Seattle, WA 98104, USA
    Vaccine 20:3292-303. 2002
    ....
  9. pmc Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant
    Yasuyuki Goto
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Vaccine 25:7450-8. 2007
    ..The results indicate that SMT/MPL-SE can be an effective vaccine candidate for use against VL...
  10. pmc Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells
    Rhea N Coler
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Infect Immun 75:4648-54. 2007
    ..The Leish-111f+MPL-SE product we report here is the first defined vaccine for leishmaniasis in human clinical trials and has completed phase 1 and 2 safety and immunogenicity testing in normal, healthy human subjects...
  11. ncbi request reprint Second-generation vaccines against leishmaniasis
    Rhea N Coler
    The Infectious Disease Research Institute, 1124 Columbia Street, Suite 600, Seattle, WA 98104, USA
    Trends Parasitol 21:244-9. 2005
    ..In addition, several antigens have been identified and characterized that might be potential vaccine candidates. In this article, we focus on advances made with second-generation vaccines against leishmaniasis...
  12. pmc Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection
    Elizabeth G Rhee
    Cellular Immunology Section, Vaccine Research Center, Bethesda, MD 20892, USA
    J Exp Med 195:1565-73. 2002
    ....
  13. ncbi request reprint Taking toll: lipid A mimetics as adjuvants and immunomodulators
    David H Persing
    Corixa, Suite 200, 1124 Columbia Street, Seattle, WA 98104, USA
    Trends Microbiol 10:S32-7. 2002
    ..Novel approaches to vaccine development could benefit from taking full advantage of the effects of these compounds on innate and adaptive responses...
  14. pmc Cloning, characterization, and serodiagnostic evaluation of Leishmania infantum tandem repeat proteins
    Yasuyuki Goto
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Infect Immun 74:3939-45. 2006
    ..Our results suggest that TR regions from the novel L. infantum proteins identified in this study are immunodominant B-cell epitopes and may represent good candidates for serodiagnosis of VL...
  15. pmc Bioinformatic identification of tandem repeat antigens of the Leishmania donovani complex
    Yasuyuki Goto
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Infect Immun 75:846-51. 2007
    ..0070, LinJ25.1100, LinJ27.0400, and LinJ29.0110, which were from the 42 uncharacterized proteins, are also antigenic. The results suggest the validity of this approach for identifying leishmanial antigens of serological significance...
  16. ncbi request reprint Immunotherapy for drug-refractory mucosal leishmaniasis
    Roberto Badaro
    Federal University of Bahia, Salvador, Brazil
    J Infect Dis 194:1151-9. 2006
    ..Immunotherapy using a mixture of killed parasites, with or without bacille Calmette-Guerin, is an alternative but is used sporadically because of inconsistent results...

Research Grants3